Current Hypertension Reports

, Volume 14, Issue 2, pp 152–159 | Cite as

Epidemiology of Obesity, the Metabolic Syndrome, and Chronic Kidney Disease

Hypertension and Metabolic Disarray: Diabetes Mellitus, Insulin Resistance, and Obesity (E Reisin, Section Editor)


The prevalence of obesity and metabolic syndrome (MetS) has increased over the past several decades and is expected to continue to increase. Although the individual components of MetS have previously been associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), until recently there were few data on the relationship between MetS itself and incident CKD and ESRD. A recent meta-analysis demonstrated an association between MetS and CKD. When pooling 10 prospective cohort studies, MetS was associated with an increased odds ratio for an estimated glomerular filtration rate (eGFR) less than 60 mL/ min per 1.73 m2 (OR, 1.55; 95% CI, 1.34–1.80). Additionally, published data suggest an association between MetS and albuminuria. Evidence suggests that lifestyle modifications such as weight reduction, reduced dietary fat intake and cholesterol, and pharmacologic treatments may reduce the burden of MetS and thus the risk for CKD, albuminuria, and ESRD.


Metabolic syndrome Obesity Chronic kidney disease Albuminuria End-stage renal disease Epidemiology Incidence Blood pressure Diabetes HDL cholesterol Triglycerides Interventions Mechanisms 


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010;303(3):235–41.PubMedCrossRefGoogle Scholar
  2. 2.
    Kelly T, Yang W, Chen CS, et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond). 2008;32(9):1431–7.CrossRefGoogle Scholar
  3. 3.
    Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5.PubMedCrossRefGoogle Scholar
  4. 4.
    • Scholze J, Alegria E, Ferri C, et al.: Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model. BMC Public Health 2010, 10:529. This reference reported current and future prevalence estimates of MetS in Germany, Spain, and Italy, suggesting that MetS is not only recognized elsewhere as a unique phenotype, but is highly prevalent in multiple world regions. CrossRefGoogle Scholar
  5. 5.
    Wild SH, Byrne CD: The global burden of the metabolic syndrome and its consequences for diabetes and cardiovascular disease. In The Metabolic Syndrome. Edited by Byrne, CD and Wild, SH. Chichester, UK: John Wiley & Sons, Ltd.; 2006:1–41.Google Scholar
  6. 6.
    Perneger TV, Whelton PK, Klag MJ. History of hypertension in patients treated for end-stage renal disease. J Hypertens. 1997;15(4):451–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Brancati FL, Whelton PK, Randall BL, et al. Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA. 1997;278(23):2069–74.PubMedCrossRefGoogle Scholar
  8. 8.
    Muntner P, Coresh J, Smith JC, et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000;58(1):293–301.PubMedCrossRefGoogle Scholar
  9. 9.
    Allison DB, Fontaine KR, Manson JE, et al. Annual deaths attributable to obesity in the United States. JAMA. 1999;282(16):1530–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. JAMA. 1999;282(16):1523–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Visscher TL, Seidell JC. The public health impact of obesity. Ann Rev Public Health. 2001;22:355–75.CrossRefGoogle Scholar
  12. 12.
    Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999–2000. JAMA. 2002;288(14):1723–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Gu D, Reynolds K, Wu X, et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet. 2005;365(9468):1398–405.PubMedCrossRefGoogle Scholar
  14. 14.
    Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–607.PubMedCrossRefGoogle Scholar
  15. 15.
    Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–53.PubMedCrossRefGoogle Scholar
  16. 16.
    Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–52.PubMedCrossRefGoogle Scholar
  17. 17.
    Alberti KG, Zimmet P, Shaw J. The metabolic syndrome–a new worldwide definition. Lancet. 2005;366(9491):1059–62.PubMedCrossRefGoogle Scholar
  18. 18.
    Stern MP, Williams K, Gonzalez-Villalpando C, et al. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care. 2004;27(11):2676–81.PubMedCrossRefGoogle Scholar
  19. 19.
    Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among u.s. Adults. Diabetes Care. 2004;27(10):2444–9.PubMedCrossRefGoogle Scholar
  21. 21.
    • Liu Y, Tong G, Tong W, et al.: Can body mass index, waist circumference, waist-hip ratio and waist-height ratio predict the presence of multiple metabolic risk factors in Chinese subjects? BMC Public Health 2011;11:35. In this study, BMI, waist circumference, and waist-height ratio all significantly and similarly predicted the presence of multiple metabolic risk factors in Chinese subjects. However, waist-to-hip ratio did not. Thus, the best measure of obesity is somewhat controversial. CrossRefGoogle Scholar
  22. 22.
    Gallagher D, Visser M, Sepulveda D, et al. How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? Am J Epidemiol. 1996;143(3):228–39.PubMedGoogle Scholar
  23. 23.
    Fox CS, Larson MG, Leip EP, et al. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291(7):844–50.PubMedCrossRefGoogle Scholar
  24. 24.
    Munkhaugen J, Lydersen S, Wideroe TE, et al. Prehypertension, obesity, and risk of kidney disease: 20-year follow-up of the HUNT I study in Norway. Am J Kidney Dis. 2009;54(4):638–46.PubMedCrossRefGoogle Scholar
  25. 25.
    Muntner P, Winston J, Uribarri J, et al. Overweight, obesity, and elevated serum cystatin C levels in adults in the United States. Am J Med. 2008;121(4):341–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65(4):1416–21.PubMedCrossRefGoogle Scholar
  27. 27.
    Noori N, Hosseinpanah F, Nasiri AA, et al. Comparison of overall obesity and abdominal adiposity in predicting chronic kidney disease incidence among adults. J Ren Nutr. 2009;19(3):228–37.PubMedCrossRefGoogle Scholar
  28. 28.
    de Boer IH, Sibley SD, Kestenbaum B, et al. Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. J Am Soc Nephrol. 2007;18(1):235–43.PubMedCrossRefGoogle Scholar
  29. 29.
    •• Thomas G, Sehgal AR, Kashyap SR, et al.: Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2011, 6(10):2364–2373. This meta-analysis pooled 11 studies (N = 30,146) and concluded that MetS and its components are associated with development of eGFR <60 mL/min per 1.73 m 2 and albuminuria. PubMedCrossRefGoogle Scholar
  30. 30.
    Hsu CY, McCulloch CE, Iribarren C, et al. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144(1):21–8.PubMedGoogle Scholar
  31. 31.
    Reynolds K, Gu D, Muntner P, et al. A population-based, prospective study of blood pressure and risk for end-stage renal disease in China. J Am Soc Nephrol. 2007;18(6):1928–35.PubMedCrossRefGoogle Scholar
  32. 32.
    Perry Jr HM, Miller JP, Fornoff JR, et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension. 1995;25(4 Pt 1):587–94.PubMedGoogle Scholar
  33. 33.
    Kramer HJ, Saranathan A, Luke A, et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol. 2006;17(5):1453–9.PubMedCrossRefGoogle Scholar
  34. 34.
    • Kramer H, Shoham D, McClure LA, et al.: Association of waist circumference and body mass index with all-cause mortality in CKD: The REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. Am J Kidney Dis 2011;58(2):177–185. This study examined the association between measures of adiposity and mortality in adults with CKD. The researchers found that in CKD, BMI may not be a useful predictor of mortality risk, whereas waist circumference does predict mortality risk associated with obesity. PubMedCrossRefGoogle Scholar
  35. 35.
    Teta D. Weight loss in obese patients with chronic kidney disease: who and how? J Ren Care. 2010;36 Suppl 1:163–71.PubMedCrossRefGoogle Scholar
  36. 36.
    Kramer H, Tuttle KR, Leehey D, et al. Obesity management in adults with CKD. Am J Kidney Dis. 2009;53(1):151–65.PubMedCrossRefGoogle Scholar
  37. 37.
    Eckel RH. Clinical practice. Nonsurgical management of obesity in adults. N Engl J Med. 2008;358(18):1941–50.PubMedCrossRefGoogle Scholar
  38. 38.
    NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med. 1991;115(12):956–61.Google Scholar
  39. 39.
    •• Navaneethan SD, Yehnert H, Moustarah F, et al.: Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009, 4(10):1565–1574. This systematic review analyzed the impact of weight loss interventions in patients with CKD. It reported that in CKD patients, nonsurgical weight loss interventions reduce proteinuria and prevent further decline in renal function. This suggests that weight loss may offer renal benefits in addition to the cardiovascular benefits. PubMedCrossRefGoogle Scholar
  40. 40.
    Agrawal V, Krause KR, Chengelis DL, et al. Relation between degree of weight loss after bariatric surgery and reduction in albuminuria and C-reactive protein. Surg Obes Relat Dis. 2009;5(1):20–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Muntner P, Anderson A, Charleston J, et al. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2010;55(3):441–51.PubMedCrossRefGoogle Scholar
  42. 42.
    Klag MJ, Whelton PK, Randall BL, et al. End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA. 1997;277(16):1293–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Vupputuri S, Batuman V, Muntner P, et al. Effect of blood pressure on early decline in kidney function among hypertensive men. Hypertension. 2003;42(6):1144–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993;118(8):577–81.PubMedGoogle Scholar
  45. 45.
    Viberti G, Mogensen CE, Groop LC, et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA. 1994;271(4):275–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329(20):1456–62.PubMedCrossRefGoogle Scholar
  47. 47.
    Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334(15):939–45.PubMedCrossRefGoogle Scholar
  48. 48.
    Ruggenenti P, Perna A, Benini R, et al. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). J Am Soc Nephrol. 1998;9(11):2096–101.PubMedGoogle Scholar
  49. 49.
    Guasch A, Parham M, Zayas CF, et al. Contrasting effects of calcium channel blockade versus converting enzyme inhibition on proteinuria in African Americans with non-insulin-dependent diabetes mellitus and nephropathy. J Am Soc Nephrol. 1997;8(5):793–8.PubMedGoogle Scholar
  50. 50.
    Levin A, Hemmelgarn B, Culleton B, et al. Guidelines for the management of chronic kidney disease. CMAJ. 2008;179(11):1154–62.PubMedCrossRefGoogle Scholar
  51. 51.
    USRDS: USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease in the United States Bethesda, MD: National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases, 2010.Google Scholar
  52. 52.
    Salpeter SR, Greyber E, Pasternak GA, et al.: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010, (4):CD002967.Google Scholar
  53. 53.
    Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.PubMedCrossRefGoogle Scholar
  54. 54.
    Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997;51(6):1908–19.PubMedCrossRefGoogle Scholar
  55. 55.
    Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med. 2004;140(3):167–74.PubMedGoogle Scholar
  56. 56.
    Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008;336(7645):645–51.PubMedCrossRefGoogle Scholar
  57. 57.
    Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59(1):260–9.PubMedCrossRefGoogle Scholar
  58. 58.
    NKF: KDOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease. Available at Accessed October 2011.
  59. 59.
    Lea J, Cheek D, Thornley-Brown D, et al. Metabolic syndrome, proteinuria, and the risk of progressive CKD in hypertensive African Americans. Am J Kidney Dis. 2008;51(5):732–40.PubMedCrossRefGoogle Scholar
  60. 60.
    Sarafidis PA, Lasaridis AN. Insulin resistance and endothelin: another pathway for renal injury in patients with the cardiometabolic syndrome? J Cardiometab Syndr. 2008;3(3):183–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Sarafidis PA, Ruilope LM. Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. Am J Nephrol. 2006;26(3):232–44.PubMedCrossRefGoogle Scholar
  62. 62.
    Chung S, Park CW. Role of peroxisome proliferator-activated receptor alpha in diabetic nephropathy. Diabetes Metab J. 2011;35(4):327–36.PubMedCrossRefGoogle Scholar
  63. 63.
    Tesauro M, Canale MP, Rodia G, et al. Metabolic syndrome, chronic kidney, and cardiovascular diseases: role of adipokines. Cardiol Res Pract. 2011;2011:653182.PubMedGoogle Scholar
  64. 64.
    Kasiske BL, O’Donnell MP, Garvis WJ, et al. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res. 1988;62(2):367–74.PubMedGoogle Scholar
  65. 65.
    Harrison D, Griendling KK, Landmesser U, et al. Role of oxidative stress in atherosclerosis. Am J Cardiol. 2003;91(3A):7A–11.PubMedCrossRefGoogle Scholar
  66. 66.
    Lucove J, Vupputuri S, Heiss G, et al. Metabolic syndrome and the development of CKD in American Indians: The Strong Heart Study. Am J Kidney Dis. 2008;51:21–8.PubMedCrossRefGoogle Scholar
  67. 67.
    Tozawa M, Iseki C, Tokashiki K, et al. Metabolic syndrome and risk of developing chronic kidney disease in Japanese adults. Hypertens Res. 2007;30:937–43.PubMedCrossRefGoogle Scholar
  68. 68.
    Watanabe H, Obata H, Watanabe T, et al. Metabolic syndrome and risk of development of chronic kidney disease: The Niigata Preventive Medicine Study. Diabetes Metab Res Rev. 2010;26:26–32.PubMedCrossRefGoogle Scholar
  69. 69.
    Bonnet F, Marre M, Halimi JM, et al. Waist circumference and the metabolic syndrome predict the development of elevated albuminuria in non-diabetic subjects: The DESIR Study. J Hypertens. 2006;24:1157–63.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Rikki M. Tanner
    • 1
  • Todd M. Brown
    • 2
  • Paul Muntner
    • 1
  1. 1.Department of EpidemiologyUniversity of Alabama at BirminghamBirminghamUSA
  2. 2.Department of MedicineUniversity of Alabama at BirminghamBirminghamUSA

Personalised recommendations